Johns Hopkins Researchers Present Advances in Prostate Cancer Program at the Annual Meeting of the American Urological Associat
May 25 2006 - 10:00AM
PR Newswire (US)
Markers Discovered That May Aid in the Prediction of Recurrence of
Prostate Cancer FREMONT, Calif., May 25 /PRNewswire-FirstCall/ --
Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced the discovery of
two biomarkers that may aid in the management of prostate cancer,
including for the detection, staging, and prediction of recurrence.
These markers, a fragment of protein C inhibitor (PCI) and
complement factor 4 (C4a), were identified in two separate studies,
a multi-institutional study encompassing over 400 men and a
five-year longitudinal study following 104 patients after radical
prostatectomy. These studies demonstrated that PCI provides
information useful for the detection and staging of prostate
cancer, and the combined use of pre-surgery PCI, PSA, and C4a is
predictive of prostate cancer recurrence. The work was performed by
Dr. Daniel Chan and Dr. Zhen Zhang of the Johns Hopkins Medical
Institutions as part of our research collaboration. "We are pleased
with the progress of our ongoing collaborative prostate cancer
program with Johns Hopkins. These findings address a critical
aspect of the management of prostate cancer, as the ability to
predict recurrence can help physicians and patients understand
better the aggressiveness of disease," said Gail S. Page, President
and CEO of Ciphergen. "The discovery of PCI using Ciphergen's
technology demonstrates its ability to identify markers directly
related to the disease process, since PCI is present in seminal
fluid and directly interacts with PSA. Further validation is
underway." About Ciphergen Ciphergen is dedicated to translating
protein biomarkers and panels of biomarkers into protein molecular
diagnostic tests that improve patient care. We are also focused on
providing collaborative R&D services through our Biomarker
Discovery Center(R) laboratories for biomarker discovery for new
diagnostic tests as well as pharmacoproteomic services for improved
drug toxicology, efficacy and theranostic assays. Ciphergen
develops, manufactures and markets a family of ProteinChip(R)
Systems and services for clinical, research and process proteomics
applications. ProteinChip Systems enable protein discovery,
validation, identification and assay development to provide
researchers with predictive, multi-marker assay capabilities and a
better understanding of biological function at the protein level.
Additional information about Ciphergen can be found at
http://www.ciphergen.com/. Safe Harbor Statement Note Regarding
Forward-Looking Statements: This press release contains
forward-looking statements. For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding the usefulness of certain
biomarkers to predict the recurrence of disease and the ability of
Ciphergen to use such biomarkers in the creation of diagnostic
tests. Actual results may differ materially from those projected in
such forward-looking statements due to various factors, including
the risk that Ciphergen may not be able to develop diagnostic tests
based on the discoveries of certain biomarkers. Investors should
consult Ciphergen's filings with the Securities and Exchange
Commission, including its Form 10-K filed March 17, 2006, for
further information regarding these and other risks related to the
Company's business. NOTE: Ciphergen, ProteinChip and Biomarker
Discovery Center are registered trademarks of Ciphergen Biosystems,
Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue
Carruthers, Investor Relations of Ciphergen Biosystems, Inc.,
+1-510-505 2297 Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2024 to Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2023 to Jun 2024